These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 22133994)

  • 1. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
    Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.
    Malaguti P; Vari S; Cognetti F; Fabi A
    Anticancer Res; 2013 Jan; 33(1):21-8. PubMed ID: 23267124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR in mantle cell lymphoma: current and future directions.
    Smith SM
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in the treatment of hormone receptor-positive breast cancer.
    Chavez-MacGregor M; Gonzalez-Angulo AM
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
    Carraway H; Hidalgo M
    Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting endocrine resistance: is there a role for mTOR inhibition?
    Sheri A; Martin LA; Johnston S
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S79-85. PubMed ID: 21115426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming endocrine resistance in breast cancer: role of the PI3K and the mTOR pathways.
    Provenzano A; Kurian S; Abraham J
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):143-7. PubMed ID: 23406555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New therapeutical strategies in metastatic hormone-dependent breast cancer].
    Vilquin P; Cohen P; Maudelonde T; Tredan O; Treilleux I; Bachelot T; Heudel PE
    Bull Cancer; 2015 Apr; 102(4):367-80. PubMed ID: 25799877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.
    O'Regan R; Hawk NN
    Expert Opin Ther Targets; 2011 Jul; 15(7):859-72. PubMed ID: 21476875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM
    Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.
    De P; Miskimins K; Dey N; Leyland-Jones B
    Cancer Treat Rev; 2013 Aug; 39(5):403-12. PubMed ID: 23352077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
    Chollet P; Abrial C; Tacca O; Mouret-Reynier MA; Leheurteur M; Durando X; Curé H
    Clin Breast Cancer; 2006 Oct; 7(4):336-8. PubMed ID: 17092402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.